デフォルト表紙
市場調査レポート
商品コード
1412522

ヘモグロビン異常症市場:適応症、治療、診断、エンドユーザー別-世界予測2024-2030年

Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
ヘモグロビン異常症市場:適応症、治療、診断、エンドユーザー別-世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヘモグロビン異常症市場規模は2023年に26億3,000万米ドルと推定され、2024年には27億9,000万米ドルに達すると予測され、2030年にはCAGR33.02%で194億6,000万米ドルに達する見込みです。

ヘモグロビン異常症の世界市場

主な市場の統計
基準年[2023] 26億3,000万米ドル
予測年[2024] 27億9,000万米ドル
予測年 [2030] 194億6,000万米ドル
CAGR(%) 33.02%
ヘモグロビン異常症 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはヘモグロビン異常症市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、ヘモグロビン異常症市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客ベース、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、各社の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競争特性に関する貴重な洞察が得られます。このように詳細レベルを拡大することで、ベンダーはより多くの情報に基づいた意思決定を行い、市場での競争力を獲得するための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓:有利な新興市場を深く掘り下げ、成熟した市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制当局の承認、特許状況、製造能力について徹底的な評価を行います。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-ヘモグロビン異常症市場の市場規模および予測は?

2-ヘモグロビン異常症市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-ヘモグロビン異常症市場における技術動向と規制の枠組みは?

4-ヘモグロビン異常症市場における主要ベンダーの市場シェアは?

5-ヘモグロビン異常症市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 一般的な希少血液関連疾患の蔓延
      • ヘモグロビン異常症治療を求める患者数の増加
      • 新しいヘモグロビン異常症療法に対する規制当局からの承認の増加
    • 抑制要因
      • ヘモグロビン異常症の処理に伴う高額なコスト
    • 機会
      • ヘモグロビン異常症処理に関する継続的な研究開発活動
      • ヘモグロビン異常症治療のための新しい薬物療法と診断法の利用可能性
    • 課題
      • ヘモグロビン異常症療法に関する認識の欠如
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 ヘモグロビン異常症市場適応症別

  • 鎌状赤血球症
  • サラセミア
    • アルファサラセミア
    • ベータサラセミア

第7章 ヘモグロビン異常症市場治療別

  • 輸血
  • 骨髄および幹細胞移植
  • 化学療法
  • 治癒療法
  • 遺伝子治療
  • ヒドロキシ尿素
  • 鉄キレーション療法

第8章 ヘモグロビン異常症市場診断別

  • 遺伝子検査
  • ヘモグロビン等電点電気泳動(Hb IEF)
  • ヘモグロビン溶解度検査
  • 高速液体クロマトグラフィーによるヘモグロビン
  • ヘモグロビン電気泳動(Hb ELP)
  • 日常的な赤血球(RBC)数

第9章 ヘモグロビン異常症市場:エンドユーザー別

  • クリニック
  • 診断研究所
  • 病院

第10章 南北アメリカのヘモグロビン異常症市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のヘモグロビン異常症市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのヘモグロビン異常症市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Alnylam Pharmaceuticals, Inc.
    • Bio-Rad Laboratories Inc.
    • Biogen Inc.
    • Bluebird Bio, Inc.
    • Bristol Myers Squibb
    • CRISPR Therapeutics AG
    • Danaher Corporation
    • Emmaus Life Sciences Inc.
    • Gamida Cell Ltd.
    • Genetix Biotech Asia Pvt. Ltd
    • Laboratory Corporation
    • Medunik USA Inc.
    • Merck & Co. Inc.
    • Nexcelom Bioscience LLC
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer, Inc.
    • Prolong Pharmaceuticals, LLC
    • Regenacy Pharmaceuticals, Inc.
    • Sangamo Therapeutics, Inc.
    • Sanofi S.A.
    • Sebia
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd
    • Sysmex Corporation
    • Vertex Pharmaceuticals Incorporated
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
  • FIGURE 7. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 12. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HEMOGLOBINOPATHIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOGLOBINOPATHIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 9. HEMOGLOBINOPATHIES MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HEMOGLOBINOPATHIES MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. HEMOGLOBINOPATHIES MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HEMOGLOBINOPATHIES MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEMOGLOBINOPATHIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEMOGLOBINOPATHIES MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HEMOGLOBINOPATHIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HEMOGLOBINOPATHIES MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HEMOGLOBINOPATHIES MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 20. HEMOGLOBINOPATHIES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN ISOELECTRIC FOCUSING (HB IEF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN SOLUBILITY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS (HB ELP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. HEMOGLOBINOPATHIES MARKET SIZE, BY ROUTINE RED BLOOD CELL (RBC) COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. HEMOGLOBINOPATHIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. HEMOGLOBINOPATHIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 240. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. HEMOGLOBINOPATHIES MARKET LICENSE & PRICING
目次
Product Code: MRR-C002B1C9951F

[186 Pages Report] The Hemoglobinopathies Market size was estimated at USD 2.63 billion in 2023 and expected to reach USD 2.79 billion in 2024, at a CAGR 33.02% to reach USD 19.46 billion by 2030.

Global Hemoglobinopathies Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.63 billion
Estimated Year [2024] USD 2.79 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 33.02%
Hemoglobinopathies Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hemoglobinopathies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemoglobinopathies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hemoglobinopathies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories Inc., Biogen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CRISPR Therapeutics AG, Danaher Corporation, Emmaus Life Sciences Inc., Gamida Cell Ltd., Genetix Biotech Asia Pvt. Ltd, Laboratory Corporation, Medunik USA Inc., Merck & Co. Inc., Nexcelom Bioscience LLC, Novartis AG, PerkinElmer Inc., Pfizer, Inc., Prolong Pharmaceuticals, LLC, Regenacy Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sebia, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sysmex Corporation, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hemoglobinopathies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Sickle Cell Disease
    • Thalassemia
      • Alpha Thalassemia
      • Beta thalassemia
  • Treatment
    • Blood Transfusion
    • Bone Marrow & Stem Cell Transplant
    • Chemotherapy
    • Curative Therapy
    • Gene Therapy
    • Hydroxyurea
    • Iron Chelation Therapy
  • Diagnosis
    • Genetic Testing
    • Haemoglobin Isoelectric Focusing (Hb IEF)
    • Haemoglobin Solubility Test
    • Hemoglobin by High Performance Liquid Chromatography
    • Hemoglobin electrophoresis (Hb ELP)
    • Routine Red Blood Cell (RBC) Count
  • End-User
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hemoglobinopathies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemoglobinopathies Market?

3. What are the technology trends and regulatory frameworks in the Hemoglobinopathies Market?

4. What is the market share of the leading vendors in the Hemoglobinopathies Market?

5. Which modes and strategic moves are suitable for entering the Hemoglobinopathies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hemoglobinopathies Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of common rare blood-related diseases
      • 5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
      • 5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with hemoglobinopathies treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
      • 5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about hemoglobinopathies therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hemoglobinopathies Market, by Indication

  • 6.1. Introduction
  • 6.2. Sickle Cell Disease
  • 6.3. Thalassemia
    • 6.4.1. Alpha Thalassemia
    • 6.4.2. Beta thalassemia

7. Hemoglobinopathies Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Bone Marrow & Stem Cell Transplant
  • 7.4. Chemotherapy
  • 7.5. Curative Therapy
  • 7.6. Gene Therapy
  • 7.7. Hydroxyurea
  • 7.8. Iron Chelation Therapy

8. Hemoglobinopathies Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. Genetic Testing
  • 8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
  • 8.4. Haemoglobin Solubility Test
  • 8.5. Hemoglobin by High Performance Liquid Chromatography
  • 8.6. Hemoglobin electrophoresis (Hb ELP)
  • 8.7. Routine Red Blood Cell (RBC) Count

9. Hemoglobinopathies Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals

10. Americas Hemoglobinopathies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hemoglobinopathies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hemoglobinopathies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Alnylam Pharmaceuticals, Inc.
    • 14.1.3. Bio-Rad Laboratories Inc.
    • 14.1.4. Biogen Inc.
    • 14.1.5. Bluebird Bio, Inc.
    • 14.1.6. Bristol Myers Squibb
    • 14.1.7. CRISPR Therapeutics AG
    • 14.1.8. Danaher Corporation
    • 14.1.9. Emmaus Life Sciences Inc.
    • 14.1.10. Gamida Cell Ltd.
    • 14.1.11. Genetix Biotech Asia Pvt. Ltd
    • 14.1.12. Laboratory Corporation
    • 14.1.13. Medunik USA Inc.
    • 14.1.14. Merck & Co. Inc.
    • 14.1.15. Nexcelom Bioscience LLC
    • 14.1.16. Novartis AG
    • 14.1.17. PerkinElmer Inc.
    • 14.1.18. Pfizer, Inc.
    • 14.1.19. Prolong Pharmaceuticals, LLC
    • 14.1.20. Regenacy Pharmaceuticals, Inc.
    • 14.1.21. Sangamo Therapeutics, Inc.
    • 14.1.22. Sanofi S.A.
    • 14.1.23. Sebia
    • 14.1.24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
    • 14.1.25. Sysmex Corporation
    • 14.1.26. Vertex Pharmaceuticals Incorporated
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing